In the 21st century, the rate at which cases of a disease can spread across the world is unprecedented, as highlighted by the 2019-2020 COVID-19 (SARS-CoV-2) pandemic, with daily confirmed cases
Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss preliminary results for the period ending 31st Dec 2019. Alastair talks us through the highlights, outlines the key objectives to
Avacta Group’s Alastair Smith discusses their recent partnership with Adeptrix Corporation in this exclusive interview with DirectorsTalk.
Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and research reagents, today announced its preliminary results for the 17-month period ending 31 December 2019. Operating highlights LG Chem partnership: progressing well
Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss the recently announced a partnership with Adeptrix Corporation. Alastair explains how the test works, the benefits of this type of
Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has today announced that it has entered into a collaboration with Adeptrix (Beverly, MA, USA) to develop a high throughput COVID-19 antigen test
A test to diagnose coronavirus in just 20 minutes could be available in a few weeks after a major breakthrough. In only four weeks and well ahead of schedule, Whittlesford-based
Avacta Group’s Alastair Smith discusses generating over 50 affimer reagents in only 4 weeks for their partnership with Cytiva in this exclusive interview with DirectorsTalk.
Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss the news that in just 4 weeks its successfully generated multiple Affimer reagents that bind the SARS-COV-2 viral antigen as
Listen below to the interview with Alastair that was broadcast on Talk Radio at 9:30am on 17th April 2020. Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
